Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 40 of 40 results for eczema

  1. Atopic Dermatitis (Eczema)

    Discontinued [GID-NG10289]

  2. Appeal panel membership

    working and voluntary activities. David previously worked at the National Eczema Society and the international non-governmental...

  3. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

  4. Reslizumab for treating severe eosinophilic asthma (TA479)

    Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.

  5. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

  6. Otitis media with effusion in under 12s (NG233)

    This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.

  7. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

  8. The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional

  9. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  10. Offer less invasive treatments before surgery for varicose veins

    Surgery should only be offered to treat varicose veins if other less invasive treatments are unsuitable for patients, according to latest guidance from NICE.